Target- |
MechanismProtein biosynthesis inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Canada |
First Approval Date31 Dec 1984 |
/ Not yet recruitingPhase 3 A Phase 3 Randomized, Multi-Center, Placebo-Controlled, Masked Study to Evaluate the Clinical Efficacy and Safety of Fusidic Acid 1% Viscous Topical Antibiotic Eye Drops for the Treatment of Suspected Bacterial Conjunctivitis
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
100 Clinical Results associated with Baxis Pharmaceuticals, Inc.
0 Patents (Medical) associated with Baxis Pharmaceuticals, Inc.
100 Deals associated with Baxis Pharmaceuticals, Inc.
100 Translational Medicine associated with Baxis Pharmaceuticals, Inc.